Cargando…

A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms

One of the most promising drugs recently approved for the treatment of various types of cancer is dacomitinib, which belongs to the tyrosine kinase inhibitor class. The US Food and Drugs Administration (FDA) has recently approved dacomitinib as a first-line treatment for patients suffering from non-...

Descripción completa

Detalles Bibliográficos
Autores principales: Alossaimi, Manal A., Elmansi, Heba, Alajaji, Mai, Altharawi, Ali, Altamimi, Abdulmalik S. A., Magdy, Galal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005270/
https://www.ncbi.nlm.nih.gov/pubmed/36903599
http://dx.doi.org/10.3390/molecules28052351
_version_ 1784905039017410560
author Alossaimi, Manal A.
Elmansi, Heba
Alajaji, Mai
Altharawi, Ali
Altamimi, Abdulmalik S. A.
Magdy, Galal
author_facet Alossaimi, Manal A.
Elmansi, Heba
Alajaji, Mai
Altharawi, Ali
Altamimi, Abdulmalik S. A.
Magdy, Galal
author_sort Alossaimi, Manal A.
collection PubMed
description One of the most promising drugs recently approved for the treatment of various types of cancer is dacomitinib, which belongs to the tyrosine kinase inhibitor class. The US Food and Drugs Administration (FDA) has recently approved dacomitinib as a first-line treatment for patients suffering from non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The current study proposes the design of a novel spectrofluorimetric method for determining dacomitinib based on newly synthesized nitrogen-doped carbon quantum dots (N-CQDs) as fluorescent probes. The proposed method is simple and does not require pretreatment or preliminary procedures. Since the studied drug does not have any fluorescent properties, the importance of the current study is magnified. When excited at [Formula: see text] , N-CQDs exhibited native fluorescence at [Formula: see text] , which was quantitatively and selectively quenched by the increasing concentrations of dacomitinib. The developed method involved the simple and green microwave-assisted synthesis of N-CQDs, using orange juice as a carbon source and urea as a nitrogen source. The characterization of the prepared quantum dots was performed using different spectroscopic and microscopic techniques. The synthesized dots had consistently spherical shapes and a narrow size distribution and demonstrated optimal characteristics, including a high stability and a high fluorescence quantum yield ([Formula: see text]). When assessing the effectiveness of the proposed method, several optimization factors were considered. The experiments demonstrated highly linear quenching behavior across the concentration range of [Formula: see text] with a correlation coefficient (r) of 0.999. The recovery percentages were found to be in the range of 98.50–100.83% and the corresponding relative standard deviation (%RSD) was 0.984. The proposed method was shown to be highly sensitive with a limit of detection (LOD) as low as [Formula: see text]. The type of mechanism by which quenching took place was also investigated by different means and was found to be static with a complementary inner filter effect. For quality purposes, the assessment of the validation criteria adhered to the ICHQ2(R1) recommendations. Finally, the proposed method was applied to a pharmaceutical dosage form of the drug (Vizimpro(®) Tablets) and the obtained results were satisfactory. Considering the eco-friendly aspect of the suggested methodology, using natural materials to synthesize N-CQDs and water as a diluting solvent added to its greenness profile.
format Online
Article
Text
id pubmed-10005270
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100052702023-03-11 A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms Alossaimi, Manal A. Elmansi, Heba Alajaji, Mai Altharawi, Ali Altamimi, Abdulmalik S. A. Magdy, Galal Molecules Article One of the most promising drugs recently approved for the treatment of various types of cancer is dacomitinib, which belongs to the tyrosine kinase inhibitor class. The US Food and Drugs Administration (FDA) has recently approved dacomitinib as a first-line treatment for patients suffering from non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The current study proposes the design of a novel spectrofluorimetric method for determining dacomitinib based on newly synthesized nitrogen-doped carbon quantum dots (N-CQDs) as fluorescent probes. The proposed method is simple and does not require pretreatment or preliminary procedures. Since the studied drug does not have any fluorescent properties, the importance of the current study is magnified. When excited at [Formula: see text] , N-CQDs exhibited native fluorescence at [Formula: see text] , which was quantitatively and selectively quenched by the increasing concentrations of dacomitinib. The developed method involved the simple and green microwave-assisted synthesis of N-CQDs, using orange juice as a carbon source and urea as a nitrogen source. The characterization of the prepared quantum dots was performed using different spectroscopic and microscopic techniques. The synthesized dots had consistently spherical shapes and a narrow size distribution and demonstrated optimal characteristics, including a high stability and a high fluorescence quantum yield ([Formula: see text]). When assessing the effectiveness of the proposed method, several optimization factors were considered. The experiments demonstrated highly linear quenching behavior across the concentration range of [Formula: see text] with a correlation coefficient (r) of 0.999. The recovery percentages were found to be in the range of 98.50–100.83% and the corresponding relative standard deviation (%RSD) was 0.984. The proposed method was shown to be highly sensitive with a limit of detection (LOD) as low as [Formula: see text]. The type of mechanism by which quenching took place was also investigated by different means and was found to be static with a complementary inner filter effect. For quality purposes, the assessment of the validation criteria adhered to the ICHQ2(R1) recommendations. Finally, the proposed method was applied to a pharmaceutical dosage form of the drug (Vizimpro(®) Tablets) and the obtained results were satisfactory. Considering the eco-friendly aspect of the suggested methodology, using natural materials to synthesize N-CQDs and water as a diluting solvent added to its greenness profile. MDPI 2023-03-03 /pmc/articles/PMC10005270/ /pubmed/36903599 http://dx.doi.org/10.3390/molecules28052351 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alossaimi, Manal A.
Elmansi, Heba
Alajaji, Mai
Altharawi, Ali
Altamimi, Abdulmalik S. A.
Magdy, Galal
A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms
title A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms
title_full A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms
title_fullStr A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms
title_full_unstemmed A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms
title_short A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms
title_sort novel quantum dots-based fluorescent sensor for determination of the anticancer dacomitinib: application to dosage forms
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005270/
https://www.ncbi.nlm.nih.gov/pubmed/36903599
http://dx.doi.org/10.3390/molecules28052351
work_keys_str_mv AT alossaimimanala anovelquantumdotsbasedfluorescentsensorfordeterminationoftheanticancerdacomitinibapplicationtodosageforms
AT elmansiheba anovelquantumdotsbasedfluorescentsensorfordeterminationoftheanticancerdacomitinibapplicationtodosageforms
AT alajajimai anovelquantumdotsbasedfluorescentsensorfordeterminationoftheanticancerdacomitinibapplicationtodosageforms
AT altharawiali anovelquantumdotsbasedfluorescentsensorfordeterminationoftheanticancerdacomitinibapplicationtodosageforms
AT altamimiabdulmaliksa anovelquantumdotsbasedfluorescentsensorfordeterminationoftheanticancerdacomitinibapplicationtodosageforms
AT magdygalal anovelquantumdotsbasedfluorescentsensorfordeterminationoftheanticancerdacomitinibapplicationtodosageforms
AT alossaimimanala novelquantumdotsbasedfluorescentsensorfordeterminationoftheanticancerdacomitinibapplicationtodosageforms
AT elmansiheba novelquantumdotsbasedfluorescentsensorfordeterminationoftheanticancerdacomitinibapplicationtodosageforms
AT alajajimai novelquantumdotsbasedfluorescentsensorfordeterminationoftheanticancerdacomitinibapplicationtodosageforms
AT altharawiali novelquantumdotsbasedfluorescentsensorfordeterminationoftheanticancerdacomitinibapplicationtodosageforms
AT altamimiabdulmaliksa novelquantumdotsbasedfluorescentsensorfordeterminationoftheanticancerdacomitinibapplicationtodosageforms
AT magdygalal novelquantumdotsbasedfluorescentsensorfordeterminationoftheanticancerdacomitinibapplicationtodosageforms